Amicus Therapeutics Inc

Financials

Flusso di cassa derivante dalle attività operative -3.92 M7.76 M-26.53 M35.66 M16.25 M 33.15 M Flussi di cassa derivanti dalle attività di investimento -20.39 M-32.86 M-5.78 M-1.3 M-6.49 M -46.43 M Liquidità derivante dalle attività di finanziamento 1.1 M-11.7 M-400 K-1.32 M14.03 M 610 K Liquidità libera -4.2 M7.55 M-28.93 M35.28 M15.95 M 29.85 M

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

FOLD

Financials

Amicus Therapeutics Inc

Notizie

Protalix: Elfabrio Struggles Against Oral Competition (NYSE:PLX)

Il titolo di Amicus Therapeutics raggiunge il massimo a 14,46 USD

Il titolo di Amicus Therapeutics raggiunge il massimo a $14,44

Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?

Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?

Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating

Arcutis Biotherapeutics Shows Market Leadership With Jump To 82 RS Rating

BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?

Le azioni di Amicus Therapeutics raggiungono il massimo a 52 settimane a 14,39 USD

Il titolo di Amicus Therapeutics raggiunge il massimo a 14,38 USD

Amicus Therapeutics stock hits 52-week high at 14.38 USD

Viking Therapeutics Stock Gets RS Rating Upgrade